1. Scrip
  2. >>Business

Artios Banks $153m On The Back Of Novartis And Merck KGaA Deals

UK Biotech Completes Impressive Series C

 
• By William Masters

Artios Pharma rides the wave of DDR enthusiasm following the recent signing of big pharma partnerships with a financing to bring its first-in-class cancer treatments into the clinic.

• Source: Alamy

Cambridge, UK-based Artios Pharma Limited, specializing in DNA damage response (DDR), has raised £110m ($153m) in a series C round to advance its novel cancer treatments into the clinic. This is following the signing of high-profile partnerships with Merck KGaA and Novartis AG in December 2020 and April 2021 respectively, which came with significant upfront payments and potentially billions of dollars in sales milestones and royalty payments.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.